AZN.UK

10,288

-0.41%↓

GSK

1,348

-4.6%↓

AZN.UK

10,288

-0.41%↓

GSK

1,348

-4.6%↓

AZN.UK

10,288

-0.41%↓

GSK

1,348

-4.6%↓

AZN.UK

10,288

-0.41%↓

GSK

1,348

-4.6%↓

AZN.UK

10,288

-0.41%↓

GSK

1,348

-4.6%↓

Search

Indivior PLC

Suletud

1,198 2.39

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1158

Max

1204

Põhinäitajad

By Trading Economics

Sissetulek

-19M

47M

Müük

-33M

266M

P/E

Sektori keskmine

330

39.857

Kasumimarginaal

17.669

Töötajad

1,030

EBITDA

-30M

76M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+17.27% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

613M

1.4B

Eelmine avamishind

1195.61

Eelmine sulgemishind

1198

Indivior PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuli 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17. juuli 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17. juuli 2025, 21:04 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17. juuli 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17. juuli 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:30 UTC

Market Talk
Tulu

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17. juuli 2025, 22:04 UTC

Market Talk
Tulu

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17. juuli 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17. juuli 2025, 21:58 UTC

Market Talk
Tulu

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17. juuli 2025, 21:57 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:47 UTC

Tulu

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17. juuli 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. juuli 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17. juuli 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17. juuli 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 21:05 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:04 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17. juuli 2025, 21:02 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

17. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Indivior PLC Prognoos

Hinnasiht

By TipRanks

17.27% tõus

12 kuu keskmine prognoos

Keskmine 1,338.04 GBX  17.27%

Kõrge 1,641.179 GBX

Madal 969.787 GBX

Põhineb 4 Wall Streeti analüütiku instrumendi Indivior PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.